Talking Medicines CLN & Distribution Commitment

Tern invests £117k in loss-making Talking Medicines, promises higher future shareholder payouts.

What the company is saying

Tern Plc announces a £117,195 investment in new unsecured convertible loan notes (CLNs) issued by Talking Medicines Limited, emphasising that these notes provide an uplifted principal value of £234,389—roughly double the cash outlay. The company highlights a 10% annual interest rate on the CLNs and stresses the potential for conversion at a 20% discount upon exit or a £2 million fundraising event. Tern frames the investment as part of a broader commitment to shareholder returns, now pledging to distribute at least 70% of net proceeds from any single investment exit over £1 million, up from the previous 50%. The announcement uses positive language, such as “pleased to commit” and “enhance our commitment,” to position the policy change as a shareholder-friendly move. There is significant emphasis on the mechanics of the investment and the illustrative distribution calculations, while operational performance of Talking Medicines is not discussed beyond headline loss and liability figures. The tone is upbeat and forward-looking, with aspirational references to “revolutionising” the healthcare advertising market, but little detail on near-term operational catalysts.

What the data suggests

The disclosed numbers confirm Tern’s £117,195 investment in CLNs, which are structured to provide a principal value of £234,389 and accrue 10% interest annually. These notes are convertible only if Talking Medicines achieves a £2 million fundraising or an exit event, both of which are uncertain and not imminent. Tern’s total holding in Talking Medicines now stands at approximately 23.8% equity and £1.02 million in CLNs, with the combined audited book value at £1.7 million as of December 2025. Talking Medicines itself is in a weak financial position, reporting unaudited net liabilities of £1.4 million and a £0.51 million loss for 2024, with no evidence of profitability or positive cash flow. The company provides illustrative calculations for shareholder distributions but these are hypothetical and contingent on future exits. There is no evidence of realised exits, actual distributions, or operational turnaround. The data is detailed on investment structure but thin on operational or financial progress at the portfolio company level.

Analysis

The announcement is positive in tone, highlighting a new investment in convertible loan notes and an increased commitment to shareholder distributions. However, the measurable progress is limited: the only realised actions are the investment itself and the adjustment of distribution policy, both of which are structural rather than operational achievements. The majority of forward-looking claims (such as the 70% distribution commitment and references to future exits) are contingent on successful exits or fundraising events that are not imminent or guaranteed. The benefits from the investment (conversion or exit) are long-dated, with the CLNs maturing in 2029 if no exit occurs, and Talking Medicines is currently loss-making with net liabilities. The capital outlay is material relative to the company's holding, but there is no immediate earnings impact or evidence of operational turnaround. The language around 'revolutionising' the healthcare advertising market and enhanced shareholder returns inflates the narrative beyond what the current financials support.

Risk flags

• ●Talking Medicines is loss-making and has unaudited net liabilities of £1.4 million, indicating a weak balance sheet and raising questions about its ability to achieve a profitable exit or fundraising event. This matters because the value of Tern’s CLNs and any potential conversion or repayment depend on Talking Medicines’ financial health.
• ●The 70% shareholder distribution commitment is entirely forward-looking and contingent on exits over £1 million, with no evidence of recent exits or actual distributions at this rate. This introduces the risk that the policy change is promotional rather than actionable in the near term.
• ●The investment’s return profile is highly dependent on a successful exit or fundraising by Talking Medicines, but the only triggers for conversion are a £2 million fundraising or an exit event, both of which are speculative given the current financial trajectory. If neither occurs, capital is locked until 2029, exposing Tern to prolonged illiquidity and potential further deterioration in asset value.

Bottom line

Tern’s new investment in Talking Medicines increases its exposure to a company with persistent losses and negative net assets, while offering shareholders a higher promised share of future exit proceeds—if and when those exits materialise. The structure of the CLNs is designed to enhance returns in a successful outcome, but the lack of operational progress or imminent liquidity events at Talking Medicines makes this a long-term and speculative play. The upbeat language around shareholder returns and market disruption is not matched by evidence of realised gains or improving fundamentals. For this announcement to become actionable, Tern would need to report actual exits, distributions, or a turnaround at Talking Medicines. The key takeaway is that while the policy shift sounds attractive, its value is entirely contingent on future events that currently lack supporting evidence.

Announcement summary

(AIM:TERN) Tern Plc has invested £117,195 in new unsecured convertible loan notes (CLNs) issued by Talking Medicines Limited. The CLNs provide Tern with an uplifted principal value of £234,389, approximately double the value of the new funds invested. The CLNs carry an interest rate of 10 per cent. per annum and are convertible on either an exit or a fundraising of at least £2 million by Talking Medicines, at a 20 per cent discount to the exit or fundraising price. If neither an exit nor a relevant fundraising occurs, the CLNs will mature on 21 November 2029, aligning with approximately £0.79 million of convertible loan notes already held by Tern in Talking Medicines. As at 31 December 2025, Tern's equity and convertible loan note holding in Talking Medicines had a total audited book value of approximately £1.7 million, and following the issue of the CLNs, Tern will hold approximately 23.8% of Talking Medicines' equity and an increased total convertible loan note holding of approximately £1.02 million. The Tern board has increased its commitment to shareholders, now pledging a distribution or capital return of at least 70% of the net proceeds from the exit of any individual investment over £1 million, up from the previous 50%. Talking Medicines had unaudited net liabilities of approximately £1.4 million and incurred an unaudited loss for the year of approximately £0.51 million for the year ended 31 December 2024.

Disagree with this article?